Parkinson's Is Not One Disease: Why Experts Are Changing the Search for a Cure

For many years, the medical world has treated Parkinson’s as a single, uniform condition. It has a clear set of defining motor symptoms—tremors, stiffness, and slowness—which look similar from one person to the next. Because of this apparent similarity, the search for a cure has naturally focused on finding one single drug that would successfully treat all patients with PD. However, a groundbreaking new perspective, strongly supported by recent scientific research, firmly suggests that this universal approach is fundamentally flawed. Experts are now arguing that Parkinson’s disease is not one single illness, but is actually a complex collection of several different, but related, disorders. A Spectrum, Not a Single Target Imagine the visible symptoms of Parkinson’s disease as the tip of an iceberg. While the motor problems may appear deceptively consistent across people, the biological reasons for the disease, hidden beneath the surface, are incredibly varied. This new understanding, known as heterogeneity, suggests that PD might, in reality, be a spectrum of five, ten, or even more different conditions that all eventually lead to similar motor difficulties. The reason for this dramatic variability comes down to both where the disease starts and what biological machinery goes wrong. The Different Origins of the Disease The scientific community is now exploring theories that Parkinson’s disease can be divided into distinct origins: the "Body-First" type and the "Brain-First" type. In the Body-First type, the disease appears to begin in the digestive system, travelling up the long vagus nerve to the brain. This can lead to early non-motor symptoms like constipation or loss of smell, sometimes years before any movement problems appear. In the Brain-First type, the pathology begins directly in the brain stem. The way the disease progresses, and the specific brain areas that are hit first, can drastically change the course of the illness and the symptoms a person experiences. Genetic and Environmental Factors For some individuals, specific genetic faults play a huge role in determining their PD subtype. For example, mutations in genes such as GBA or LRRK2 can predispose someone to an atypical form of the disease that progresses in a certain way. For others, the primary driver might be environmental factors, such with prolonged exposure to specific industrial chemicals or pesticides. These different genetic and environmental triggers interact with each other, leading to unique biological changes—such as different types of inflammation or protein clumping—inside the nerve cells. Varied Cellular Damage While the abnormal clumping of a protein called alpha-synuclein is considered the key pathological feature of all Parkinson’s, the timing, extent, and precise location of this cellular damage vary widely. This explains why one person might experience severe stiffness and tremors early on (motor-dominant), while another might be plagued by non-motor issues like rapid eye movement sleep disorder, mood swings, or cognitive issues first (non-motor dominant). The Problem with the Old Search for a Cure If PD is indeed a collection of multiple distinct disorders, this understanding completely changes how we must look for effective treatments. In the past, clinical trials for new drugs were designed to test the medication on a large, broad group of patients who all simply shared a general PD diagnosis. If a new drug was, in fact, highly effective, but only for one specific subtype—say, the "genetic GBA subtype"—its overall positive effect would be diluted or statistically lost across the larger, mixed trial group. The trial would then be labelled a failure, even though the drug might have been a breakthrough for a subset of those involved. By viewing PD as one monolithic disease, the scientific community may have inadvertently caused the failure of many potentially helpful, but highly targeted, therapies. The Future: Precision Medicine This new research perspective is not disheartening; rather, it provides a clear and exciting roadmap to a more effective future. The solution lies in shifting the focus towards Precision Medicine. Precision Medicine is already revolutionising cancer treatment, and the idea is to apply the same principles to Parkinson’s. This means moving away from a 'one-size-fits-all' pill and towards a deeply personalised treatment plan designed for the individual patient’s specific disease type. How Precision Medicine Will Work The process will involve two critical steps. The first is Patient Stratification, where doctors will use advanced testing—such as deep genetic analysis, specific protein measurements in the spinal fluid (biomarkers), and advanced brain imaging—to determine the exact biological mechanisms driving PD in that patient. This process, called stratification, divides the large PD population into smaller, biologically uniform groups. The second step is Targeted Therapies. Once the specific subtype is identified, the patient can be precisely matched with a therapy designed to target that particular biological cause. For example, a drug that works well for a PD subtype driven by high levels of inflammation would only be given to patients confirmed to have that inflammatory profile. This personalised approach means clinical trials will become much smaller, more focused, and therefore far more likely to prove if a drug works for a specific group of people, leading to faster development of bespoke treatments. In short, the new understanding is that we must stop searching for "one universal cure." Instead, the effort must be directed at finding the right cure for the right type of Parkinson’s, ushering in an era of far more tailored and effective patient care.